Molecular Insights into Severe Pediatric Traumatic Brain Injury via Integrated Omics
Overview
This study integrates whole blood transcriptomics and serum metabolomics to characterize molecular responses in children with severe traumatic brain injury (TBI). Analysis across acute and subacute phases identified distinct gene expression changes and metabolite alterations, revealing potential therapeutic targets for secondary brain injury.
Background
Severe traumatic brain injury in children leads to significant morbidity, including chronic physical, behavioral, and cognitive impairments. Despite advances in understanding TBI pathobiology, no effective therapies have emerged from clinical trials targeting secondary injury mechanisms. Protein biomarkers have diagnostic value, but mechanistic pathways remain poorly defined. Integrating transcriptomics and metabolomics offers a comprehensive approach to elucidate molecular cascades underlying secondary brain injury and identify novel intervention points.
Data Highlights
Timepoint
Sample Type
Analysis Method
Key Features
Hospital Day 0 (12–24 h)
Whole blood RNA, Serum
RNAseq, DI/LC-MS/MS, 1H NMR
Initial acute phase molecular signatures
Hospital Day 2 (36–60 h)
Whole blood RNA, Serum
RNAseq, DI/LC-MS/MS, 1H NMR
Progression of acute phase changes
Hospital Day 9 (204–228 h)
Whole blood RNA, Serum
RNAseq, DI/LC-MS/MS, 1H NMR
Subacute phase molecular alterations
Controls
Single blood sample
RNAseq, Metabolomics
Baseline molecular profiles
Key Findings
Severe pediatric TBI induces significant differential gene expression in whole blood, with stringent criteria (Bonferroni p < 0.05, log2 fold change > 2 or < −2) identifying key transcripts.
Integrated transcriptomic and metabolomic profiling across three timepoints reveals dynamic molecular changes during acute and subacute phases of injury.
Pathway enrichment analyses highlight immune and inflammatory cascades as central to secondary brain injury mechanisms.
Deconvolution of RNAseq data using CIBERSORTx indicates shifts in immune cell populations post-injury.
Metabolomics identified altered serum metabolites linked to energy metabolism and oxidative stress, correlating with clinical severity measures.
Cross-sectional analysis design strengthens the validity of biomarker discovery by using independent observations at each timepoint.
Clinical Implications
The identification of specific molecular signatures and pathways involved in secondary brain injury provides potential targets for therapeutic intervention during the acute and subacute phases of severe pediatric TBI. Integrated omics approaches may enhance prognostic accuracy and guide personalized treatment strategies. Future clinical trials should consider these molecular targets to improve outcomes in this vulnerable population.
Conclusion
This pioneering pediatric study demonstrates that integrated transcriptomic and metabolomic analyses can uncover novel molecular mechanisms underlying severe TBI. These findings lay the groundwork for developing targeted therapies aimed at mitigating secondary brain injury in children.
References
Epidemiology and impact of pediatric TBI
Protein biomarkers in TBI diagnosis and prognosis
Integrated omics methodologies in clinical research
by Elora Hussain, Jeremy W. Prokop, Emily Nonnemacher, Nadia Ashrafi, Ali Yilmaz, Romana Ashrafi Mimi, Abdullah Khalid, Karolis Krinickis, Vilija Lomeikaite, Lena Sanfilippo, Kylie Maxton, Jacob Charron, Charitha Subrahmanya, Austin Goodyke, Annie Needs, Daniel R. Woldring, Caleb P. Bupp, Nicholas Hartog, Juozas Gordevicius, Stewart F. Graham, Surender Rajasekaran
